XIPERE

Peak

triamcinolone acetonide

NDAINJECTIONSUSPENSION
Approved
Oct 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7

Mechanism of Action

Corticosteroid Hormone Receptor Agonists

Pharmacologic Class:

Corticosteroid

Clinical Trials (5)

NCT04598542Phase 1Completed

Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers

Started Oct 2020
NCT02294656Phase 1Completed

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

Started Nov 2014
4 enrolled
CYSTOID MACULAR EDEMA
NCT00449072Phase 4Completed

Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)

Started Mar 2007
299 enrolled
Rhinitis, Allergic, Perennial
NCT00476918Phase 1Unknown

Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema

Started Jul 2006
60 enrolled
Diabetic RetinopathyDiabetic Macular Edema
NCT00242580Phase 3Completed

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

Started Sep 2005
111 enrolled
Macular DegenerationChoroidal Neovascularization

Loss of Exclusivity

LOE Date
Apr 16, 2040
171 months away
Patent Expiry
Apr 16, 2040

Patent Records (4)

Patent #ExpiryTypeUse Code
8636713
May 2, 2027
U-3234
9636332
Nov 8, 2033
U-3234
9937075
May 2, 2034
Product
12419833
Apr 16, 2040
Product
U-3234